Who
Gregory K. Chow
CFO
Company insider
Files Form 4 as: CFO, Sutro Biopharma; Executive VP & CFO, Aptose Biosciences.
In numbers
- Trades disclosed
- 21
- Buys
- 3
- Sells
- 1
- Bought
- $56K
- Sold
- $766K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 2 Jan 2019
- Last trade
- 2 Jun 2026
- Last filed
- 2 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jun 2026filed 2 Jun 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 2 Jun 2026filed 2 Jun 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 2 Jun 2026filed 2 Jun 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 2 Jun 2026filed 2 Jun 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 23 Dec 2025filed 29 Dec 2025 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,200 at $0.00 | filing |
| 15 Oct 2025filed 16 Oct 2025 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Bought | $16K19,750 at $0.81 | filing |
| 2 Jun 2025filed 2 Jun 2025 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —275,000 at $0.00 | filing |
| 2 Jun 2025filed 2 Jun 2025 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 4 Jan 2021filed 6 Jan 2021 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code A | —343,000 at $0.00 | filing |
| 10 Jul 2020filed 10 Jul 2020 | Aptose Biosciences | SEC FORM 4 Sold | $766K126,668 at $6.05 | filing |
| 10 Mar 2020filed 7 May 2020 | Aptose Biosciences | SEC FORM 4 Code A | —225,000 at $0.00 | filing |
| 10 Mar 2020filed 12 Mar 2020 | Aptose Biosciences | SEC FORM 4 Code A | —225,000 at $0.00 | filing |
| 31 Jan 2020filed 3 Feb 2020 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code A | —1,200,000 at $0.00 | filing |
| 5 Jun 2019filed 7 Jun 2019 | Aptose Biosciences | SEC FORM 4 Bought | $14K7,500 at $1.84 | filing |
| 13 Mar 2019filed 14 Mar 2019 | Aptose Biosciences | SEC FORM 4 Bought | $17K10,000 at $1.74 | filing |
| 13 Mar 2019filed 14 Mar 2019 | Aptose Biosciences | SEC FORM 4 Bought | $8,9505,000 at $1.79 | filing |
News
Tenaya Therapeutics (NASDAQ:TNYA) versus Sutro Biopharma (NASDAQ:STRO) Head-To-Head ComparisonSTRO · themarketsdaily.com · 20 Oct 2026
0 headlines in the last 90 days name Gregory K. Chow; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.